Vilacto Bio and Carmen Electra to develop new skin cream

Biotech firm Vilacto Bio has signed a licensing agreement with American actress Carmen Electra to develop a new skin cream.

It is claimed the new Carmen Electra by Vilact will be designed to leverage the self-healing power of skin to allow cellular regeneration for soft and healthy looking skin.

The agreement is intended to validate the marketing data that revealed demand for natural skincare products.

Vilacto Bio CEO Gert Anderson said: “Vilacto Bio takes pride in our fully patented Lactoactive that has earned its place in the upper echelon of high-quality skin products and the recent endorsement of Carmen Electra is evidence of that.”

Developed by the firm’s Denmark team, Lactoactive is reported to have shown above average effects during various studies for the treatment of skin concerns such as ageing, psoriasis, diabetes, and inflammatory diseases.

The firm intends to further develop the Lactoactive molecule to enhance the quality of its retail and medical skin cream products, with plans to license the molecule for pharmaceutical industry.

Carmen Electra by Vilact is said to feature the clinical standards of the firm’s Vilact brand of skincare offerings, which include skin lotion, baby skin cream, 24/7 heel repair cream, and maternal skin cream.